PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN THE BIOLOGIC ERA: IMPLICATIONS FOR PRACTICE

Supplement 2 to Volume 78

November 2011

www.ccjm.org/content/78/Suppl_2

Supplement Editor

LEONARD CALABRESE, DO
Cleveland Clinic

Contents

Introduction ................................................................. S2
Leonard Calabrese, DO

History and current concepts in the pathogenesis of PML .............. S3
Eugene O. Major, PhD

The clinical features of PML ......................................... S8
Joseph R. Berger, MD

Pharmacovigilance and PML in the oncology setting ................. S13
Charles L. Bennett, MD, PhD, MPP

Multiple sclerosis, natalizumab, and PML: Helping patients decide .... S18
Richard A. Rudick, MD

HIV-associated PML: Changing epidemiology and clinical approach ........ S24
David M. Simpson, MD, FRCP, FAAN

PML and rheumatology: The contribution of disease and drugs .... S28
Eamonn S. Molloy, MD, MS, MRCPI

Advances in the management of PML: Focus on natalizumab .......... S33
Robert Fox, MD

A rational approach to PML for the clinician .......................... S38
Leonard Calabrese, DO

Copyright © 2011 The Cleveland Clinic Foundation. All rights reserved.
The statements and opinions expressed in this supplement to Cleveland Clinic Journal of Medicine are those of the authors and not necessarily those of The Cleveland Clinic Foundation, its Board of Trustees, or Genentech. They do not necessarily represent formal practice guidelines in effect at Cleveland Clinic.

Cleveland Clinic Journal of Medicine [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published 12 times yearly by The Cleveland Clinic Foundation.


Postmaster address changes: Cleveland Clinic Journal of Medicine, 9500 Euclid Avenue, TR4-04, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): 216-444-2661 (phone); 216-444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).

Printed in USA.